National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
SoRelle
R
R
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002752:Chlorthalidone / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications* / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control*; D009316:National Institutes of Health (U.S.); D017211:Treatment Failure; D014481:United States
D000317:Adrenergic alpha-Antagonists; D000924:Anticholesteremic Agents; D004232:Diuretics; D017292:Doxazosin; D002752:Chlorthalidone